ASX-listed ear implant maker Cochlear announced that its total profits for fiscal year 2010 were $155.2 million, up nineteen percent. Total revenues were $734.8 million, up six percent.

In a statement from Cochlear, CEO and President Dr. Chris Roberts said that the majority of implants sold in the second half were the Nucleus 5 System.

“The launch of the Nucleus 5 has resulted in a game change across multi dimensions, including recipient hearing performance, miniaturization, scalable manufacturing and the building blocks for scaling the clinical pathway,” Dr. Roberts said. He said that the product, available in 50 countries, will continue to underpin Cochlear’s growth into FY2011.

Cochlear implant (CI) sales which included accessories and sound processor upgrades were $603.7 million, down two percent, but up 13 percent in constant currency. Cochlear implant unit sales increased 13 percent to 21,023 units.

The launch of the Nucleus 5 System has now been rolled out in nearly 50 countries. The features and performance are acknowledged as a game changer in the industry. Recipient performance data are now available and show continued clinically significant hearing improvement.

In the Americas, sales rose 18 percent to $307.6 million, following the Cochlear Nucleus 5 product releases. EMEA (Europe, Middle East and Africa) sales were up seven percent to $291.5 million, while Asia Pacific sales rose to $97.1 million.

Cochlear’s shares closed at $70.25 on the ASX Wednesday.